U.S. Specialty Stores Stock News

NYSE:PK
NYSE:PKHotel and Resort REITs

Park Hotels Ties Finance And Operations With Sean Dell’Orto Promotion

Park Hotels & Resorts (NYSE:PK) has appointed Sean M. Dell’Orto as Chief Operating Officer, adding to his existing roles as Chief Financial Officer and Treasurer. The expanded role gives Dell’Orto broader oversight of operations alongside his current finance responsibilities. For Park Hotels & Resorts, which last closed at $11.31, this leadership shift puts one executive at the center of both financial and operational decisions. The stock shows mixed performance, with a 5.4% return over the...
NasdaqGS:IMCR
NasdaqGS:IMCRBiotechs

Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals

If you are wondering whether Immunocore Holdings is priced attractively right now, this article will walk through how its current share price stacks up against several valuation checks. The stock last closed at US$32.30, with a 10.0% return over the past year but declines of 1.2% over 7 days, 2.5% over 30 days and 4.4% year to date. These movements can change how investors think about both upside potential and risk. Recent news around Immunocore has focused on its position within the...
NasdaqGS:ZD
NasdaqGS:ZDInteractive Media and Services

Ziff Davis Refocuses On Core Business As RetailMeNot Bets On Cash Back

RetailMeNot, a Ziff Davis (NasdaqGS:ZD) company, has launched a Guaranteed Cash Back program that offers assured and stackable rewards for shoppers. Ziff Davis completed its exit from the Games Publishing business in Q4 2025, refocusing on its core operations. For you as an investor, these moves sit at the heart of what Ziff Davis does today: a mix of digital media, subscription based services, and advertising supported platforms. RetailMeNot’s Guaranteed Cash Back program reflects how...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention

CorMedix (NasdaqGM:CRMD) has agreed to acquire Melinta Therapeutics, adding seven approved therapies to its commercial portfolio. The transaction expands CorMedix's presence in hospital and acute care settings through a broader anti infective offering. The deal marks a shift from a single product focused model toward a multi asset commercial platform. For you as an investor, CorMedix has largely been known for its focus on infection prevention products in high risk settings. By bringing...
NasdaqGS:DNUT
NasdaqGS:DNUTHospitality

Assessing Krispy Kreme (DNUT) Valuation After The New Oreo Doughnut Collection Launch

Krispy Kreme (DNUT) is back in the spotlight after expanding its collaboration with the Oreo brand, rolling out a limited time cookie themed doughnut collection that sits alongside its recent earnings release. See our latest analysis for Krispy Kreme. The Oreo collaboration and recent earnings update come after a sharp rebound in the short term, with a 7 day share price return of 23.76% and 30 day share price return of 18.67%. However, this sits against a 1 year total shareholder return...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit (INTU) Margin Expansion Tests Bearish Spending Narratives After Q2 2026 Results

Intuit (INTU) has put solid numbers on the board for Q2 2026, with revenue of US$4.7b, basic EPS of US$2.48 and net income of US$693m, backed by trailing 12 month EPS of US$15.53 on revenue of US$20.1b. The company has seen quarterly revenue shift from US$3.9b in Q2 2025 to US$4.7b in Q2 2026, while basic EPS moved from US$1.68 to US$2.48 over the same period. This sets the context for trailing earnings growth of 42.9% and a net margin of 21.6%. For investors, the combination of higher recent...
NYSE:ENOV
NYSE:ENOVMedical Equipment

Enovis Weighs US$501.3m Impairment Against Nebula Led Organic Growth

Enovis (NYSE:ENOV) recorded a goodwill impairment charge of over $500 million in Q4 2025, tied to changes in its business mix and accounting assumptions. The company reported strong organic growth in key segments in the same period, supported by new product launches. Recently introduced products, including the Nebula Stem and OrthoDrive Impactor, are gaining traction, with Nebula competing directly against established peers. For investors tracking Enovis, the combination of a large goodwill...
NasdaqGS:MBLY
NasdaqGS:MBLYAuto Components

Mobileye Deepens ADAS Partnerships And Moves Closer To Level 4 Scale

Mobileye Global (NasdaqGS:MBLY) is adding Elektrobit’s Linux platform to its Mobileye Drive system to support Level 4 autonomous driving. The company recently secured a major U.S. OEM win for its advanced driver assistance systems, expanding its ADAS pipeline. Mobileye signed a SuperVision agreement with Mahindra & Mahindra, positioning itself as a Tier 1 supplier and opening new geographic markets. Mobileye Global, known for its driver assistance and autonomous driving technology, is...
NasdaqGS:AVAH
NasdaqGS:AVAHHealthcare

Is Aveanna Healthcare Holdings (AVAH) Still Attractively Priced After Its Recent Multi Year Surge

If you are wondering whether Aveanna Healthcare Holdings is still attractively priced after its recent run, you are not alone. This article focuses on what the current share price could imply about value. The stock last closed at US$7.36, with returns of 0.3% over 7 days, a 10.8% decline over 30 days, an 8.9% decline year to date, and a 72.8% gain over the past year, as well as a very large 3 year return of around 4x. Recent coverage has centred on Aveanna's role in home and pediatric...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

Does The Share Price Of uniQure (QURE) Reflect Its Gene Therapy Prospects?

If you are wondering whether uniQure’s current share price reflects its true worth, this breakdown is designed to help you weigh what you are paying against what you are getting. The stock closed at US$15.63, with returns of a 33.3% decline over 7 days, a 32.1% decline over 30 days, a 33.2% decline year to date, but an 18.9% gain over the past year, which may catch the eye of investors thinking about both risk and recovery potential. Recent news around uniQure has focused on its position in...
NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

LeMaitre Vascular Links Strong 2025 Results To Higher Shareholder Returns

LeMaitre Vascular (NasdaqGM:LMAT) reported robust Q4 2025 and full-year 2025 financial results. The company announced a new US$100 million share repurchase program. Management approved a 25% dividend increase for shareholders. LeMaitre Vascular focuses on medical devices for vascular surgeons, so its performance tends to track demand for procedures that treat peripheral vascular disease and related conditions. The combination of strong quarterly and full-year 2025 figures with higher...
NYSE:NLY
NYSE:NLYMortgage REITs

Annaly Insider Sale Prompts Fresh Look At Valuation And Dividend Risk

A senior executive at Annaly Capital Management (NYSE:NLY) has sold company shares, according to a recent regulatory filing. The transaction involves insider ownership of the mortgage real estate investment trust and comes at a time when there is limited company specific news. Annaly Capital Management focuses on investing in mortgage related assets, a segment that is closely linked to interest rate policy, housing finance conditions, and broader credit markets. When an insider at a company...
NasdaqGS:OLPX
NasdaqGS:OLPXPersonal Products

Should Olaplex’s Faster No.3PLUS Launch Prompt Rethinking of Its Science-Led Brand Strategy (OLPX)?

Earlier this week, OLAPLEX Holdings, Inc. launched No.3PLUS Complete Repair Treatment, a three-minute pre-shampoo product using its patented Bond Building Technology™ and new Damage Defense Cationic Complex, supported by a “Science Never Looked So Good” campaign featuring Chloe Fineman and broad distribution across major retail and online channels. This new treatment extends OLAPLEX’s core bond-repair franchise into a faster, more convenient format, aiming to reinforce its science-led brand...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

SPS Commerce Earnings Beat Meets Insider Selling And Growth Concerns

SPS Commerce (NasdaqGS:SPSC) reported earnings per share that were ahead of expectations, highlighting resilient profitability. Shortly after the results, the CEO sold company shares, drawing attention to insider activity. Craig Hallum downgraded the stock, citing a revenue miss and a softer outlook for 2026. SPS Commerce focuses on cloud based supply chain and retail data services, giving retailers and suppliers tools to manage orders and product information. That positions the company in...
NYSE:PACS
NYSE:PACSHealthcare

PACS Group (PACS) Margin Jump To 3.6% Tests Rich 29.9x P/E Narrative

PACS Group (PACS) just wrapped up FY 2025 with Q4 revenue of US$1.4b and basic EPS of US$0.38, supported by trailing twelve month revenue of US$5.3b and EPS of US$1.23 that has been tied to very large year on year earnings growth of 243.5%. Over recent periods, the company has seen quarterly revenue move from US$1.21b in Q4 2024 to US$1.36b in Q4 2025, while quarterly EPS went from US$0.24 to US$0.38. This sets up a results season where strong reported earnings growth, margin improvement to...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

COO Share Sale Highlights GeneDx Valuation Gap And Recent Stock Pressure

GeneDx Holdings (NasdaqGS:WGS) Chief Operating Officer Bryan Dechairo has sold his entire direct shareholding in an open market transaction. The sale was executed under a Rule 10b5-1 trading plan and leaves Dechairo with no direct equity interest in the company. This insider transaction comes as GeneDx continues to report business growth and operational progress. The move comes at a time when GeneDx shares last closed at $79.71, with the stock showing mixed performance across time frames...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Applied Optoelectronics (AAOI) Narrower Q4 Loss Tests Bullish Earnings Ramp Narrative

Applied Optoelectronics (AAOI) closed out FY 2025 with fourth quarter revenue of US$134.3 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$2.0 million loss. This puts the focus squarely on how efficiently that top line is being converted into earnings. The company has seen quarterly revenue move from US$65.2 million in Q3 2024 to US$100.3 million in Q4 2024, then to US$99.9 million in Q1 2025, US$103.0 million in Q2 2025, US$118.6 million in Q3 2025...
NYSE:PNW
NYSE:PNWElectric Utilities

Pinnacle West Credit Facility Extends Liquidity While Valuation Appears Stretched

Pinnacle West Capital (NYSE:PNW) entered a new $300 million revolving credit facility, replacing its prior arrangement. The facility extends through 2031 and is intended to support general corporate purposes and ongoing infrastructure investments. For investors watching NYSE:PNW, this fresh $300 million credit line arrives with the stock around $100.3 per share, alongside returns of 13.8% year to date and 63.9% over 5 years. These figures provide a snapshot of how the market has valued the...
NYSE:PERF
NYSE:PERFSoftware

Assessing Perfect Corp (NYSE:PERF) Valuation After LashLovr Partnership And Recent Earnings

Perfect (PERF) has drawn fresh attention after partnering with True Beauty Lashes on LashLovr, an AI powered lash matching and virtual try on experience that highlights how its APIs are used in real retail journeys. See our latest analysis for Perfect. Even with the LashLovr partnership and recent earnings update, Perfect’s short term share price return has been weak, with a 30 day share price decline of 18.67% and a 1 year total shareholder return of 28.19% in the red. This points to fading...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Zscaler Q2 Loss Deepens To US$0.21 EPS And Tests Profitability Narratives

Fresh off its Q2 2026 print, Zscaler (ZS) reported revenue of US$815.8 million and a basic EPS loss of US$0.21, with net income excluding extra items at a loss of US$34.3 million, setting the tone for how investors will read the quarter. The company has seen revenue move from US$647.9 million in Q2 2025 through to US$815.8 million in Q2 2026, while quarterly basic EPS over that stretch has ranged from a loss of US$0.05 in Q2 2025 to a loss of US$0.21 in the latest quarter. As a result, the...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions

Supernus Pharmaceuticals reported record revenues in 2025. The company completed the integration of Sage Therapeutics. New products ONAPGO for Parkinson's disease and ZURZUVAE for postpartum depression were launched. The business expanded into new therapeutic areas despite supply constraints. For investors looking at NasdaqGM:SUPN, these company updates come with a stock that last closed at $54.73 and has returned 70.7% over the past year. Over 3 years the stock is up 37.5%, and over 5...
NYSE:DBRG
NYSE:DBRGCapital Markets

DigitalBridge Results Raise Questions As Guidance Pauses For SoftBank Proposal

DigitalBridge Group (NYSE:DBRG) released its latest quarterly financial results and paused regular quarterly guidance. The company decided not to host its usual earnings call, citing a proposed transaction with SoftBank Group Corp. The SoftBank proposal could lead to meaningful changes in DigitalBridge Group's business structure or ownership. DigitalBridge Group, a digital infrastructure investment firm, operates at the intersection of data centers, connectivity and related assets that...
NasdaqGS:SYBT
NasdaqGS:SYBTBanks

Is It Time To Revisit Stock Yards Bancorp (SYBT) After Recent Share Price Weakness

If you are wondering whether Stock Yards Bancorp is attractively priced or just fairly valued at its current level, you are in the right place. The share price closed at US$64.14, with returns of a 7.5% decline over 7 days, a 5.2% decline over 30 days, a 1.6% decline year to date, and a 10.4% decline over 1 year, set against gains of 18.1% over 3 years and 31.9% over 5 years. These mixed returns give investors several entry and exit points to think about, especially if you are weighing...
NasdaqGS:RMBS
NasdaqGS:RMBSSemiconductor

CFO Insider Selling At Rambus Sparks Questions On Valuation And Momentum

Rambus (NasdaqGS:RMBS) Senior Vice President and CFO Desmond Lynch has recently sold a significant number of company shares. The transaction extends an ongoing pattern, with insider sales and no insider purchases reported over the past year. Investors may watch this activity closely, as insider trading trends can influence sentiment around the stock. Rambus, trading at $99.66, has seen its share price move in different directions over multiple time frames, including a 2.9% decline over the...